scispace - formally typeset
Open AccessJournal ArticleDOI

Oral angiotensin-converting enzyme inhibitors for treatment of delayed inflammatory reaction to dermal hyaluronic acid fillers following COVID-19 vaccination-a model for inhibition of angiotensin II-induced cutaneous inflammation.

Reads0
Chats0
TLDR
In this article, the authors present four cases of delayed inflammatory reaction (DIR) to facial dermal hyaluronic acid filler rapidly following vaccination for COVID-19. All patients responded rapidly to therapy with a low dose of oral lisinopril, an angiotensin-converting enzyme inhibitor (ACE-I), which decreases the cutaneous filler-related inflammatory reaction and edema by a novel proposed mechanism.
Abstract
We present 4 cases of delayed inflammatory reaction (DIR) to facial dermal hyaluronic acid filler rapidly following vaccination for COVID-19. All DIRs occurred after a hyaluronic acid filler had been placed more than 1 year before vaccination. All patients responded rapidly to therapy with a low dose of oral lisinopril, an angiotensin-converting enzyme inhibitor (ACE-I), which decreases the cutaneous filler-related inflammatory reaction and edema by a novel proposed mechanism.

read more

Citations
More filters
Journal ArticleDOI

Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases

TL;DR: The most reported reactions in each vaccine group were COVID arm (mRNA-1273, Moderna, 61·9%), varicella zoster virus reactivation (BNT162b2, Pfizer-BioNTech, 17·2%) and urticaria (AZD1222, AstraZeneca, 21·1%) as mentioned in this paper .
Journal ArticleDOI

Cutaneous findings following COVID-19 vaccination: Review of world literature and own experience.

TL;DR: There is growing evidence that not only the novel coronavirus disease (COVID-19) but also the COVID19 vaccines can cause a variety of skin reactions as mentioned in this paper, including delayed large local skin lesions, inflammatory reactions in dermal filler or previous radiation sites or even old BCG scars.
Journal ArticleDOI

COVID-19 Vaccines and the Skin: The landscape of cutaneous vaccine reactions worldwide

TL;DR: The authors reviewed the dermatologic manifestations of COVID-19 vaccines as reported in clinical trial data and summarized additional observational reports of skin reactions to COVID19 vaccines, concluding that early-onset local injection reactions were the most common cutaneous side effects observed in clinical trials, while delayed injection reactions reported outside of clinical trials.
Journal ArticleDOI

Cutaneous adverse effects of the available COVID-19 vaccines

TL;DR: In this article, a plethora of cutaneous adverse events have been reported, most of them mild or moderate injection-site reactions, posing questions on their pathophysiology and clinical importance.
References
More filters
Journal ArticleDOI

Molecular interaction and inhibition of SARS-CoV-2 binding to the ACE2 receptor.

TL;DR: It is demonstrated, both on model surfaces and on living cells, that the receptor binding domain (RBD) serves as the binding interface within the S-glycoprotein with the ACE2 receptor and the kinetic and thermodynamic properties of this binding pocket are extracted.
Journal ArticleDOI

Multiple functions of angiotensin-converting enzyme 2 and its relevance in cardiovascular diseases.

TL;DR: This review summarizes and discusses the structure and multiple functions of ACE2 and the relevance of this key enzyme in disease pathogenesis.
Journal ArticleDOI

Human skin: source of and target organ for angiotensin II.

TL;DR: The findings suggest that the complete renin–angiotensin system is present in human skin and plays a role in normal cutaneous homeostasis as well as in human cutaneous wound healing.
Journal ArticleDOI

ACE2: The key Molecule for Understanding the Pathophysiology of Severe and Critical Conditions of COVID-19: Demon or Angel?

TL;DR: The role of ACE2 in the pathogenesis of severe and critical conditions of COVID-19 is explained and auspicious strategies for controlling the disease are discussed.
Journal ArticleDOI

Delayed-onset nodules secondary to a smooth cohesive 20 mg/mL hyaluronic acid filler: cause and management.

TL;DR: It is the authors' opinion from the patients' responses and from the literature that these nodules are immune mediated in nature and it is important to be aware of this adverse effect and have a management protocol in place.
Related Papers (5)